MIRA Pharmaceuticals appoints Alan Weichselbaum as CFO; prior CFO Michelle Yanez resigns

MIRA PHARMACEUTICALS, INC.

CFO Michelle Yanez resigned effective May 16, 2025; mutual separation not based on any disagreement.
Alan Weichselbaum appointed CFO effective May 15, 2025; also CFO of Telomir Pharma and CEO of The Wexus Group.
Employment agreement: $60,000 annual salary (part-time, 20 hrs/week), 75,000 stock options vesting over 12 months.
Weichselbaum brings over 30 years of corporate finance experience; previously at Philip Morris and Price Waterhouse.

item 1.01item 5.02item 3.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alan Weichselbaum

Chief Financial Officer

MIRA · MIRA PHARMACEUTICALS, INC.

Effective: 2025-05-15
Filed: May 21, 2025 23:59 UTC

Effective May 15, 2025, the Company appointed Alan Weichselbaum as the Chief Financial Officer of the Company.

Departed

Michelle Yanez

Chief Financial Officer

MIRA · MIRA PHARMACEUTICALS, INC.

Effective: 2025-05-16
Successor: Alan Weichselbaum
Filed: May 21, 2025 23:59 UTC

Effective May 16, 2025, Michelle Yanez and the Company mutually agreed to release Ms. Yanez from her position as Chief Financial Officer, Treasurer and Secretary of MIRA Pharmaceuticals, Inc. (the “Company”), effective on that date.

Source: SEC EDGAR

accession 0001641172-25-011936

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.